Ocular Cancer Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players involved in therapeutic development for retinoblastoma and uveal melanoma. It also features dormant and discontinued products.
Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling.
The predisposing factors include age and heredity. There are seven products in active development for this indication and companies operating in this space include Ophthotech and VCN Biosciences.
Uveal melanoma, the most common intraocular tumor, is a disease in which melanocytes, found in the part of the eye called the uvea, become cancerous. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness.
Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. There are 35 products in active development for this indication and companies operating in this space include Novartis and Eli Lilly.
Molecular targets acted on by products in development for ocular cancer include tumor antigens, kinases and growth factor receptors.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Ocular Cancer Drug Development Pipeline Review, 2018
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Ocular Cancer Report Coverage 7
2.2 Retinoblastoma - Overview 7
2.3 Uveal Melanoma - Overview 7
3 Therapeutics Development 8
3.1 Retinoblastoma 8
3.2 Uveal Melanoma 10
4 Therapeutics Assessment 16
4.1 Retinoblastoma 16
4.2 Uveal Melanoma 22
5 Companies Involved in Therapeutics Development 31
5.1 Retinoblastoma 31
5.2 Uveal Melanoma 34
6 Dormant Projects 43
6.1 Retinoblastoma 43
6.2 Uveal Melanoma 43
7 Discontinued Products 44
7.1 Uveal Melanoma 44
8 Product Development Milestones 45
8.1 Retinoblastoma 45
8.2 Uveal Melanoma 49
9 Appendix 62
9.1 Methodology 62
9.2 Coverage 62
9.3 Secondary Research 62
9.4 Primary Research 62
9.5 Expert Panel Validation 62
9.6 Contact Us 62
9.7 Disclaimer 63
1.1 List of Tables
Table 1: Number of Products under Development for Retinoblastoma 8
Table 2: Number of Products under Development by Companies, Retinoblastoma 9
Table 3: Products under Development by Companies, Retinoblastoma 10
Table 4: Number of Products under Development for Uveal Melanoma 11
Table 5: Number of Products under Development by Companies, Uveal Melanoma 12
Table 6: Number of Products under Development by Universities/Institutes, Uveal Melanoma 13
Table 7: Products under Development by Companies, Uveal Melanoma 14
Table 8: Products under Development by Universities/Institutes, Uveal Melanoma 15
Table 9: Number of Products by Stage and Target, Retinoblastoma 17
Table 10: Number of Products by Stage and Mechanism of Action, Retinoblastoma 18
Table 11: Number of Products by Stage and Route of Administration, Retinoblastoma 20
Table 12: Number of Products by Stage and Molecule Type, Retinoblastoma 21
Table 13: Number of Products by Stage and Target, Uveal Melanoma 23
Table 14: Number of Products by Stage and Mechanism of Action, Uveal Melanoma 26
Table 15: Number of Products by Stage and Route of Administration, Uveal Melanoma 29
Table 16: Number of Products by Stage and Molecule Type, Uveal Melanoma 30
Table 17: Retinoblastoma - Pipeline by APEIRON Biologics AG, H1 2018 31
Table 18: Retinoblastoma - Pipeline by EyePoint Pharmaceuticals Inc, H1 2018 31
Table 19: Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2018 32
Table 20: Retinoblastoma - Pipeline by Ophthotech Corp, H1 2018 32
Table 21: Retinoblastoma - Pipeline by PepVax Inc, H1 2018 33
Table 22: Retinoblastoma - Pipeline by VCN Biosciences SL, H1 2018 33
Table 23: Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018 34
Table 24: Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018 34
Table 25: Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018 35
Table 26: Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018 35
Table 27: Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H1 2018 36
Table 28: Uveal Melanoma - Pipeline by Delcath Systems Inc, H1 2018 36
Table 29: Uveal Melanoma - Pipeline by Eli Lilly and Co, H1 2018 37
Table 30: Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H1 2018 37
Table 31: Uveal Melanoma - Pipeline by Immunocore Ltd, H1 2018 38
Table 32: Uveal Melanoma - Pipeline by Iovance Biotherapeutics Inc, H1 2018 38
Table 33: Uveal Melanoma - Pipeline by Novartis AG, H1 2018 39
Table 34: Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2018 39
Table 35: Uveal Melanoma - Pipeline by Pfizer Inc, H1 2018 40
Table 36: Uveal Melanoma - Pipeline by Plexxikon Inc, H1 2018 40
Table 37: Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2018 41
Table 38: Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2018 41
Table 39: Uveal Melanoma - Pipeline by Tesaro Inc, H1 2018 42
Table 40: Uveal Melanoma - Pipeline by Viralytics Ltd, H1 2018 42
Table 41: Retinoblastoma - Dormant Projects, H1 2018 43
Table 42: Uveal Melanoma - Dormant Projects, H1 2018 43
Table 43: Uveal Melanoma - Discontinued Products, H1 2018 44
1.2 List of Figures
Figure 1: Number of Products under Development for Retinoblastoma 8
Figure 2: Number of Products under Development by Companies, Retinoblastoma 9
Figure 3: Number of Products under Development for Uveal Melanoma 10
Figure 4: Number of Products under Development by Companies, Uveal Melanoma 11
Figure 5: Number of Products under Development by Universities/Institutes, Uveal Melanoma 13
Figure 6: Number of Products by Targets, Retinoblastoma 16
Figure 7: Number of Products by Stage and Targets, Retinoblastoma 16
Figure 8: Number of Products by Mechanism of Actions, Retinoblastoma 17
Figure 9: Number of Products by Stage and Mechanism of Actions, Retinoblastoma 18
Figure 10: Number of Products by Routes of Administration, Retinoblastoma 19
Figure 11: Number of Products by Stage and Routes of Administration, Retinoblastoma 19
Figure 12: Number of Products by Molecule Types, Retinoblastoma 20
Figure 13: Number of Products by Stage and Molecule Types, Retinoblastoma 21
Figure 14: Number of Products by Top 10 Targets, Uveal Melanoma 22
Figure 15: Number of Products by Stage and Top 10 Targets, Uveal Melanoma 22
Figure 16: Number of Products by Top 10 Mechanism of Actions, Uveal Melanoma 24
Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Uveal Melanoma 25
Figure 18: Number of Products by Routes of Administration, Uveal Melanoma 28
Figure 19: Number of Products by Stage and Routes of Administration, Uveal Melanoma 28
Figure 20: Number of Products by Top 10 Molecule Types, Uveal Melanoma 29
Figure 21: Number of Products by Stage and Top 10 Molecule Types, Uveal Melanoma 30
Global Cancer Immunomodulator Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 125
According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 112
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Cancer Gene Therapy market:
According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 85
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
Global Kaposi Sarcoma Market Status and Outlook 2023-2028
Published: 22-Dec-2023 Price: US 3160 Onwards Pages: 107
Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Dec-2023 Price: US 3380 Onwards Pages: 118
Market Overview of Global Cancer Immunomodulator market:
According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
